Evidence summaries: new medicines
'Evidence summaries: new medicines' help commissioners, budget holders and groups such as Area Prescribing Committees make informed decisions and aid local planning on the introduction of key new medicines.
They are quality-assured summaries of the best available evidence for selected new medicines, or existing medicines with new indications or a new formulation, considered to be of significance to the NHS. The medicines selected have recently been introduced in the UK, or may be introduced in the UK in the next 6-12 months.
The strengths and weaknesses of the relevant evidence are critically reviewed, and a value assessment of each medicine is made based on its safety, effectiveness, patient factors and resource implications, but the ‘Evidence summaries: new medicines' are not formal NICE guidance.
The NHS Constitution gives patients the right to expect that decisions about the funding of medicines and treatments will be made rationally following a proper consideration of the evidence. Where there is no guidance from NICE, these summaries help to ensure consistent access to evidence for decision-makers.
Our integrated process statement sets out how we select topics and prepare the summaries.
The National Prescribing Centre (NPC) legacy website has an archive of the NPC's new medicines rapid reviews.
Published Evidence summaries: new medicines
Evidence summaries new medicines: coming soon
|Title||Expected date of
|Empagliflozin (Type 2 diabetes)||March 2014|
|Zonisamide (Monotherapy for partial seizures in children)||March 2014|
|Misoprostol pessary (Induction of labour)||March 2014|
|Canakinumab (Ilaris) Systemic juvenile idiopathic arthritis||March 2014|
|Aripiprazole prolonged - release suspension (Ablify Maintena) Maintenance treatment of schizophrenia in adults||March 2014|
This page was last updated: 06 March 2014